ALINT.PA stock surges 17.5% on April 21, 2026 intraday trading

IntegraGen SA’s ALINT.PA stock delivered a powerful intraday surge today, climbing 17.5% to €0.188 on EURONEXT. The French biotechnology company, headquartered in Évry, saw its share price jump €0.028 from the previous close of €0.16. This strong momentum reflects renewed investor interest in the genomic services provider. ALINT.PA stock has now gained 26.1% over the past month, signaling growing confidence in the company’s market position. The stock trades in the Healthcare sector, competing alongside other biotech firms in Europe’s dynamic life sciences landscape.

ALINT.PA Stock Price Action and Intraday Movement

ALINT.PA stock opened at €0.1855 and reached a high of €0.188 during today’s session. The €0.028 gain represents a 17.5% jump from yesterday’s close. Trading volume hit 1,001 shares, though this remains below the 14,333-share average daily volume. The stock’s 50-day moving average sits at €0.17681, while the 200-day average stands at €0.18688, suggesting the current price is near intermediate support levels. Year-to-date, ALINT.PA stock has climbed 39.8%, recovering from its €0.115 yearly low. However, the stock remains far below its €0.732 yearly high, indicating significant volatility in the biotech sector.

IntegraGen SA Business Model and Market Position

IntegraGen SA provides comprehensive human genome analysis services to academic researchers and life sciences companies across France. The company operates through multiple revenue streams: transcriptomics, epigenomics, DNA sequencing, and NGS testing for cancer research. IntegraGen also offers clinical-grade sequencing, pharmacogenomics, and agrigenomic services for crop and livestock genotyping. The firm developed proprietary software tools including MERCURY for oncology pathology, SIRIUS for sequencing data analysis, and Galileo for RNA-Seq exploration. With 440 full-time employees, IntegraGen generates €51.3 million in annual revenue (based on €7.77 revenue per share). As a subsidiary of OncoDNA SA, the company benefits from parent company support while maintaining operational independence.

Financial Metrics and Valuation Assessment

ALINT.PA stock trades at a price-to-sales ratio of 0.023, indicating an extremely attractive valuation relative to revenue. The company’s market cap stands at €1.23 million, making it a micro-cap stock. However, IntegraGen faces profitability challenges with a negative EPS of -€0.04 and a negative PE ratio of -4.65. The company reported negative net income per share of -€0.388 trailing twelve months. Operating margins remain strong at 82.5%, but this is offset by negative gross margins of -2.7%. The current ratio of 1.30 suggests adequate short-term liquidity. Track ALINT.PA on Meyka for real-time updates on these key metrics and financial developments.

Technical Indicators and Market Sentiment

The RSI indicator reads 54.46, suggesting neutral momentum without overbought or oversold conditions. The MACD histogram shows zero momentum, indicating a potential consolidation phase. The ADX value of 18.08 signals no clear trend direction, meaning traders should exercise caution. Bollinger Bands show the stock trading near the middle band at €0.18, with upper resistance at €0.21 and lower support at €0.15. The Stochastic %K at 28.97 indicates the stock is not yet in oversold territory. Volume-weighted indicators show MFI at 47.89, suggesting balanced buying and selling pressure. These technical signals point to a stock in transition, neither strongly bullish nor bearish.

Meyka AI Grade and Investment Outlook

Meyka AI rates ALINT.PA with a grade of B and a HOLD suggestion. The overall score of 62.78 reflects a balanced assessment across multiple factors. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating breaks down as follows: DCF analysis suggests Strong Sell, ROE shows Strong Buy potential, while ROA, debt-to-equity, PE, and price-to-book ratios all signal Strong Sell. This mixed picture reflects IntegraGen’s paradox: strong operational efficiency but persistent unprofitability. These grades are not guaranteed and we are not financial advisors. Investors should conduct thorough due diligence before making decisions.

Market Sentiment: Trading Activity and Liquidation Dynamics

Today’s 17.5% surge in ALINT.PA stock reflects renewed buying interest in the biotechnology sector. The relative volume of 1.29 indicates slightly elevated trading activity compared to the 14,333-share average. Money Flow Index at 47.89 shows balanced institutional and retail participation. The stock’s strong one-month gain of 26.1% suggests accumulation by informed traders. However, the three-month performance of 40.9% gain contrasts sharply with the one-year decline of -66.2%, indicating extreme volatility. This pattern suggests ALINT.PA stock attracts both momentum traders and value investors seeking recovery plays in beaten-down biotech names.

Final Thoughts

IntegraGen SA’s ALINT.PA stock delivered impressive intraday gains today, jumping 17.5% to €0.188 on EURONEXT. The surge reflects growing investor confidence in the French biotechnology company’s genomic services platform. While ALINT.PA stock shows strong operational metrics with 82.5% operating margins, profitability remains elusive with negative earnings. The company’s micro-cap status and extreme valuation multiples make it a speculative play rather than a core holding. Meyka AI’s B grade with a HOLD recommendation captures this duality perfectly. Year-to-date performance of 39.8% demonstrates recovery momentum, yet the stock remains 74% below its yearly high. Investors should monitor upcoming earnings announcements and cash flow developments closely. ALINT.PA stock remains suitable only for risk-tolerant traders with conviction in IntegraGen’s long-term genomic services growth story.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.